Actiphage is unique as it is able to detect and identify live mycobacteria at a very early stage of infection,...
Benefits of Actiphage
The ability to detect viable mycobacteria in the blood at an early stage of infection offers greater sensitivity in diagnosis, improved identification of carriers and more effective disease control.
Actiphage provides a highly specific and sensitive assay for the cost-effective detection of mycobacterial disease in blood and milk.
Actiphage increases the speed and effectiveness of testing..
Faster testing time
Actiphage only requires one visit to collect blood samples and analysis takes 6-8 hours to produce a result.
No ‘cool off’ period
There is no time limit between tests, enabling a continuous programme of testing to be carried out where infection has been detected or is suspected.
Highly sensitive
The test only works on viable mycobacteria. Actiphage is more sensitive than any other test currently available, able to detect fewer than 10 live mycobacteria in a 2ml blood sample.
Highly specific
The technology has in-built high-level specificity controls and is able to identify any species of mycobacteria that is susceptible to the bacteriophage, including MAP (Johne’s disease) and M.bovis (bovine TB).
High accuracy
Actiphage can reproducibly distinguish between live and dead mycobacteria, meaning that a positive result will only be delivered if there are live mycobacteria in the sample.
As a tool for differentiating vaccinated from infected hosts
Uniquely, Actiphage directly detects live mycobacteria so will always produce a negative result when used on vaccinated subjects even if they might have a positive skin test result. This opens up the possibility of, for example, the roll-out of vaccination programmes.
Contact us to find out more
Towards eradicating tuberculosis
Actiphage has potential as a non-invasive screening tool for high-risk populations. It is able to detect mycobacteria in the blood, evidence of disease progression.
This is a vital first step towards eradication of devastating mycobacterial disease.
Related content
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
23-26 April 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session at ECCMID 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session...
Phage diagnostics have potential for cost-effective detection of bacterial infections across medical, food, and agricultural industries says new review.
Phage diagnostics have potential for cost-effective detection of bacterial infections across medical, food, and agricultural industries says new review.
